Literature DB >> 17896299

Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19.

.   

Abstract

PURPOSE: To evaluate responsiveness of the National Eye Institute Visual Function Questionnaire (NEI-VFQ) to changes in visual acuity and to provide estimates of minimum clinically meaningful changes in NEI-VFQ scores.
METHODS: Data were combined from three clinical trials of submacular surgery for subfoveal choroidal neovascularization. Patients who completed NEI-VFQ interviews and visual acuity measurements at baseline and 2 years later contributed data for analysis. Data were analyzed using anchor-based (relating 2-year change in NEI-VFQ to 2-year change in visual acuity using correlation and linear regression) and distribution-based (standardized response mean) methods.
RESULTS: Of 1,015 patients enrolled, 828 patients completed NEI-VFQ interviews and had visual acuity measurements at baseline and 2 years later. Median age of patients was 75 years (range 18 to 94); all patients had subfoveal choroidal neovascularization in at least one eye. Median overall NEI-VFQ score at baseline was 69.9 (mean, 66.5). Based on anchor-based methods, a 2-line change in visual acuity of the better-seeing eye translated to a 3.4-point change in the overall NEI-VFQ score and from 2.4-point to 7.0-point changes in most subscale scores. The NEI-VFQ was sensitive to both gains and losses in visual acuity; the standardized response mean for the overall NEI-VFQ score in patients with a 2-line gain was 0.6 and for patients with 2-line loss was -0.3. In the subgroup of patients with a 2-line loss of visual acuity in the better-seeing eye, patients who had overall NEI-VFQ scores at baseline greater than the median (59.8) had an standardized response mean of -0.9 for the overall NEI-VFQ score and patients who had overall NEI-VFQ scores at baseline at or below the median had a standardized response mean of 0.2 for the overall NEI-VFQ score. A 4-point change in the overall NEI-VFQ and a 5-point change in individual subscale scores corresponded to a small clinically meaningful change.
CONCLUSIONS: The NEI-VFQ was responsive to 2-year changes in visual acuity but was less responsive to changes among patients with poorer NEI-VFQ scores at baseline. Based on this analysis, a 4-point change in the overall NEI-VFQ and a 5-point change in individual subscale scores may be considered minimum clinically meaningful within-person changes in NEI-VFQ scores.

Entities:  

Mesh:

Year:  2007        PMID: 17896299     DOI: 10.1080/09286580701502970

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  29 in total

1.  Vision-Related Functioning in Patients Undergoing Pneumatic Retinopexy vs Vitrectomy for Primary Rhegmatogenous Retinal Detachment: A Post Hoc Exploratory Analysis of the PIVOT Randomized Clinical Trial.

Authors:  Rajeev H Muni; Carolina L M Francisconi; Tina Felfeli; Michael Y K Mak; Alan R Berger; David T Wong; Filiberto Altomare; Louis R Giavedoni; Radha P Kohly; Peter J Kertes; Natalia Figueiredo; Fei Zuo; Kevin E Thorpe; Roxane J Hillier
Journal:  JAMA Ophthalmol       Date:  2020-08-01       Impact factor: 7.389

2.  Ganglion cell loss in relation to visual disability in multiple sclerosis.

Authors:  Scott D Walter; Hiroshi Ishikawa; Kristin M Galetta; Reiko E Sakai; Daniel J Feller; Sam B Henderson; James A Wilson; Maureen G Maguire; Steven L Galetta; Elliot Frohman; Peter A Calabresi; Joel S Schuman; Laura J Balcer
Journal:  Ophthalmology       Date:  2012-02-23       Impact factor: 12.079

3.  Estimating minimally important differences for two vision-specific quality of life measures.

Authors:  Brenda W Gillespie; David C Musch; Leslie M Niziol; Nancy K Janz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-06       Impact factor: 4.799

4.  Longitudinal changes in visual acuity and health-related quality of life: the Los Angeles Latino Eye study.

Authors:  Roberta McKean-Cowdin; Rohit Varma; Ron D Hays; Joanne Wu; Farzana Choudhury; Stanley P Azen
Journal:  Ophthalmology       Date:  2010-06-08       Impact factor: 12.079

5.  Psychological and cognitive determinants of vision function in age-related macular degeneration.

Authors:  Barry W Rovner; Robin J Casten; Robert W Massof; Benjamin E Leiby; William S Tasman
Journal:  Arch Ophthalmol       Date:  2011-07

Review 6.  [Value-based medicine for glaucoma].

Authors:  C Hirneiss; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

7.  Vision-Related Quality-of-Life Outcomes in the Mycotic Ulcer Treatment Trial I: A Randomized Clinical Trial.

Authors:  Jennifer Rose-Nussbaumer; N Venkatesh Prajna; K Tiruvengada Krishnan; Jeena Mascarenhas; Revathi Rajaraman; Muthiah Srinivasan; Anita Raghavan; Catherine E Oldenburg; Kieran S O'Brien; Kathryn J Ray; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya; Jeremy D Keenan
Journal:  JAMA Ophthalmol       Date:  2015-06       Impact factor: 7.389

8.  Quality of life in adults with strabismus.

Authors:  Melinda Y Chang; Federico G Velez; Joseph L Demer; Sherwin J Isenberg; Anne L Coleman; Stacy L Pineles
Journal:  Am J Ophthalmol       Date:  2014-12-09       Impact factor: 5.258

9.  Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.

Authors:  Meidong Zhu; Wijeyanthy Wijeyakumar; Adil R Syed; Nichole Joachim; Thomas Hong; Geoffrey K Broadhead; Haitao Li; Kehui Luo; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-30       Impact factor: 3.117

10.  A low-vision rehabilitation program for patients with mild cognitive deficits.

Authors:  Heather E Whitson; Diane Whitaker; Guy Potter; Eleanor McConnell; Fay Tripp; Linda L Sanders; Kelly W Muir; Harvey J Cohen; Scott W Cousins
Journal:  JAMA Ophthalmol       Date:  2013-07       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.